ADMA Biologics Inc. is trading 5.9% down at $7.50 in pre-market trading as the stock continues to face pressure from recent negative developments.
- The decline follows a series of announcements from law firms in early June investigating the company for potential securities law violations on behalf of shareholders.
- These investigations stem from a March 2026 short-seller report by Culper Research, which alleged the company engaged in a "channel stuffing scheme" to inflate its 2025 revenue figures.
- The company also withdrew its long-term financial guidance in early May, citing competitive dynamics in the U.S. plasma products market, which has added to investor uncertainty.